IN THE CLAIMS:

Please cancel claims 3, 5, and 11, without prejudice. Please amend claims 1-2, 6-10, and 12-15 in accordance with 37 C.F.R. § 1.121.

1. (Amended) A method of treating [cell proliferative diseases] cancer comprising administration in a therapeutic regimen of [an] a panerb B inhibitor [of at least one erb B tyrosine kinase] and at least one antineoplastic agent selected from the group consisting of gemcitabine, paclitaxel, docetaxel, cisplatin, carboplatin, etoposide, adriamycin, topotecan, CPT-11, capecitabine, [or] and pharmaceutically acceptable salts thereof[, or ionizing radiation].

2. (Amended) The method of Claim 1 wherein said panerb B inhibitor [of the erbB tyrosine kinase] is an irreversible inhibitor.

3. (Canceled)

4. (Original) The method according to Claim 2 wherein said inhibitor is N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.

5. (Canceled)

6. (Amended) The method according to Claim 1 wherein said at least one [said] antineoplastic agent is gemcitabine or a pharmaceutically acceptable salt thereof.

7. (Amended) The method according to Claim [6] 1 wherein said at least one [said] antineoplastic agent is a taxane or a pharmaceutically acceptable salt thereof.

8. (Amended) [A combination] The method according to Claim 1 wherein said at least one antineoplastic agent is selected from the group consisting of paclitaxel [or] and docetaxel.

9. (Amended) A method of treating [a hyperproliferative cellular disorder] cancer comprising administered to a mammal in need of treatment an amount of at least one panerb B [erbB] tyrosine kinase inhibitor and at least one antineoplastic agent according to Claim 1 in an amount sufficient to inhibit [cellular hyperproliferation] cancer cell growth.

10. (Amended) The method of Claim 9 wherein said cancer is selected from the group [comprising] consisting of solid tumors, non-small cell lung cancer, squamous cell carcinoma, glioma, small cell lung carcinoma, endometrial cancer, thyroid cancer,

melanoma, colorectal cancer, bladder cancer, renal cell cancer, pancreatic cancer, head and neck cancer such as esophageal [or] cancer, cervical cancers, ovarian cancer, myeloma, prostate cancer, sarcomas, chronic myelogenous leukemia, and breast cancer.

11. (Canceled)

12. (Amended) The method of Claim [1] 4 comprising administering [CI-1033] said inhibitor in a therapeutic regimen with at least one antineoplastic agent selected from the group [comprising] consisting of gemcitabine, paclitaxel, taxotere, cisplatin, carboplatin, etoposide, adriamycin, topotecan, CPT-11, and capecitabine[, or ionizing radiation].

13. (Amended) The method according to Claim 2, wherein the antineoplastic agent is administered prior to the panerb B [erbB] tyrosine kinase inhibitor.

14. (Amended) The method according to Claim 2, wherein the antineoplastic agent is administered at the same approximate time as the panerb B tyrosine kinase inhibitor .

15. (Amended) The method according to Claim 2, wherein the antineoplastic agent is administered [following] after the panerb B tyrosine kinase inhibitor .